Barclays analyst Balaji Prasad maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $10.00. The company’s shares closed last Friday at $5.96.
According to TipRanks, Prasad is a 3-star analyst with an average return of 2.2% and a 45.93% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Idexx Laboratories, and Dr Reddy’s Laboratories.
Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $20.75.
See Insiders’ Hot Stocks on TipRanks >>
RVNC market cap is currently $523.4M and has a P/E ratio of -1.19.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics (RVNC) Company Description:
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
Read More on RVNC:
